Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) secrete deoxycytidine, which confers resistance to gemcitabine. In particular, deoxycytidine...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Pei Pei, Gregori, Alessandro, Firuzi, Omidreza, Dahele, Max, Sminia, Peter, Peters, Godefridus J., Giovannetti, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398063/
https://www.ncbi.nlm.nih.gov/pubmed/32775041
http://dx.doi.org/10.1186/s40164-020-00176-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398063/
https://www.ncbi.nlm.nih.gov/pubmed/32775041
http://dx.doi.org/10.1186/s40164-020-00176-0

Ejemplares similares